{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:19:26Z","timestamp":1758125966418,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>This investigation assessed the clinical outcomes and adverse effects of combination therapy using sofosbuvir (SOF) and daclatasvir (DCV) among dialysis-dependent patients infected with hepatitis C virus (HCV) genotypes 1b or 2a in real-world settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective, single-arm interventional trial comprising 16maintenance hemodialysis patients (14 with HCV-1b, 2 with HCV-2a). Participants received SOF-DCV combination therapy over 24\u202fweeks with monitoring at weeks 4, 12, and 24 during treatment, plus a follow-up assessment 12\u202fweeks post-treatment completion. The primary outcome measure was sustained virologic response at 12\u202fweeks post-treatment (SVR12). Secondary endpoints included therapeutic tolerance and safety profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All 16 participants completed the prescribed treatment regimen. Demographic characteristics revealed a mean age of 57.0\u202fyears, male predominance (75%), average dialysis duration of 7.0\u202fyears, and mean body weight of 63.0\u202fkg. Five patients (31.3%) had compensated cirrhosis. Liver function parameters remained stable throughout the study period. Rapid virologic response (RVR) was documented in 87.5% (14\/16) of participants, while end-of-treatment response (ETR) and SVR12 were both achieved in 93.8% (15\/16) of cases. All cirrhotic patients (5\/5) ultimately attained SVR12. The therapeutic regimen demonstrated favorable tolerability, with no treatment discontinuations due to adverse events. One participant was lost to follow-up. APRI scores significantly decreased from baseline (0.56) to week 24 (0.20, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). Reported adverse reactions included headache, fatigue, nausea (each 6.3%), and anemia (18.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The 12-week SOF-DCV combination demonstrated robust therapeutic efficacy and acceptable safety profiles in hemodialysis patients infected with HCV genotypes 1b or 2a, including those with compensated cirrhosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1576654","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:47:18Z","timestamp":1752126438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study"],"prefix":"10.3389","volume":"12","author":[{"given":"Kaili","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","article-title":"The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies","volume":"14","author":"Fabrizi","year":"2007","journal-title":"J Viral Hepat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ekir.2022.11.008","article-title":"A systematic review of direct-acting antivirals for hepatitis C in advanced CKD","volume":"8","author":"Balk","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/lt.25424","article-title":"Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era","volume":"25","author":"Cotter","year":"2019","journal-title":"Liver Transpl"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5009\/gnl18240","article-title":"Efficacy and safety of daclatasvir and asunaprevir in patients with hepatitis C virus genotype 1b infection on hemodialysis","volume":"13","author":"Lee","year":"2019","journal-title":"Gut Liver"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","article-title":"Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis","volume":"51","author":"Toyoda","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","article-title":"Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C","volume":"51","author":"Suda","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"14332","DOI":"10.1038\/s41598-020-71205-5","article-title":"Efficacy and safety of sofosbuvir in the treatment of hepatitis C among patients on hemodialysis: a systematic review and meta-analysis","volume":"10","author":"Shehadeh","year":"2020","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12882-019-1631-4","article-title":"Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial","volume":"20","author":"Cheema","year":"2019","journal-title":"BMC Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10620-017-4749-x","article-title":"Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment","volume":"63","author":"Chan","year":"2018","journal-title":"Dig Dis Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3390\/app15063157","article-title":"Interaction between human microbiota, immune system, and hepatitis C virus infection: a narrative review","volume":"15","author":"Frumento","year":"2025","journal-title":"Appl Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s11096-015-0144-x","article-title":"Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection","volume":"37","author":"Yang","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1576654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:38:09Z","timestamp":1752154689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1576654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":18,"alternative-id":["10.3389\/fmed.2025.1576654"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1576654","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"article-number":"1576654"}}